ABL1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ABL2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ABL2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ACVR1B is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ACVR1B status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 3 clinical trials for bladder carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ALK status and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

APC is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ATM is an inclusion eligibility criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ATM status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

ATR is an inclusion eligibility criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ATR status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

ATRX is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BAP1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BLM is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BRAF is an inclusion eligibility criterion in 3 clinical trials for bladder carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and bladder carcinoma as inclusion criteria, 3 are phase 2 (3 open) [3].

BRCA1 is an inclusion eligibility criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

BRCA2 is an inclusion eligibility criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

BRD4 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRD4 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND1 is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 status and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDK12 is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDK12 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN1A is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDKN1B is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDKN2A is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

CHD4 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CHEK2 status and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CSF1R is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CYLD is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CYLD status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DICER1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DICER1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DNMT3A is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DOT1L is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DOT1L status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 4 clinical trials for bladder carcinoma, of which 4 are open and 0 are closed. Of the trials that contain EGFR status and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

EPCAM is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 5 clinical trials for bladder carcinoma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [3].

ERBB3 is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

EXO1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FANCA is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCC is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCG is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 4 clinical trials for bladder carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FGFR1 status and bladder carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (1 open) [3].

FGFR2 is an inclusion eligibility criterion in 4 clinical trials for bladder carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FGFR2 status and bladder carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 6 clinical trials for bladder carcinoma, of which 4 are open and 2 are closed. Of the trials that contain FGFR3 status and bladder carcinoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (1 open), and 1 is no phase specified (1 open) [3].

Erdafitinib has evidence of efficacy in patients with FGFR3 mutation in bladder carcinoma [3].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

GATA3 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

HGF is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IKBKE is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IKBKE status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDM6A is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 0 are open and 2 are closed. Of the trials that contain KDM6A status and bladder carcinoma as inclusion criteria, 2 are phase 1 (0 open) [3].

KDR is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

KEAP1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KIT is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

KMT2C is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2C status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2D is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 0 are open and 2 are closed. Of the trials that contain KMT2D status and bladder carcinoma as inclusion criteria, 2 are phase 1 (0 open) [3].

KRAS is an inclusion eligibility criterion in 4 clinical trials for bladder carcinoma, of which 2 are open and 2 are closed. Of the trials that contain KRAS status and bladder carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (1 open) [3].

MAGI2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAGI2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAP3K1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MED12 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MEN1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MEN1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MET is an inclusion eligibility criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MET status and bladder carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MLH1 is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH1 status and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH2 is an inclusion eligibility criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MSH2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MSH6 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

MST1R is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MTOR is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NBN is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NF1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NF2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NRG1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NSD1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 status and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

PCNA is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3C2B is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3CA is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3CA status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

PIK3CB is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CB status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PMS2 status and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

POLD1 is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLD1 status and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

POLE is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE status and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

PTCH1 is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

PTPN11 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTPN11 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RB1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RET is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RFC1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC3 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC4 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC5 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ROS1 is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RPA1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA3 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA4 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SETD2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SETD2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCA2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCA4 is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 0 are open and 2 are closed. Of the trials that contain SMARCA4 status and bladder carcinoma as inclusion criteria, 2 are phase 1 (0 open) [3].

SMARCB1 is an inclusion eligibility criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCB1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

SMO is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SOX9 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SOX9 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SS18 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SS18 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SSBP1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SSX1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX2B is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX4 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SSX4 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains STAG2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

STK11 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Erdafitinib has evidence of efficacy in patients with TACC3 mutation in bladder carcinoma [3].

TAF1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TBX3 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TBX3 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TET2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TP53 is an inclusion eligibility criterion in 3 clinical trials for bladder carcinoma, of which 1 is open and 2 are closed. Of the trials that contain TP53 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Everolimus has evidence of efficacy in patients with TSC1 mutation in bladder carcinoma [3].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VHL is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

XPO1 is an inclusion eligibility criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains XPO1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].